A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Trial Profile

A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs Perampanel (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms Study-335
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Apr 2018 Results of a post-hoc analysis from NCT00735397, NCT01618695, NCT01161524 and NCT02307578 studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 05 Dec 2017 Results of post hoc analysis of open label extension studies, presented at the 71st Annual Meeting of the American Epilepsy Society.
    • 21 Aug 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top